Mutational determinants of epigenetic instablity in myeloid malignancies

Seminars in Oncology

Volumn 39, Issue 1, 2012, Pages 80-96

  Jankowska, Anna M ^a   Szpurka, Hadrian ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE; HISTONE DEMETHYLASE; HISTONE METHYLTRANSFERASE; POLYCOMB GROUP PROTEIN; UNTRANSLATED RNA;

ARTICLE; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE FUSION; GENOMIC INSTABILITY; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC CELL; HISTONE MODIFICATION; HUMAN; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; RNA INTERFERENCE; SOMATIC MUTATION;

EPIGENOMICS; HEMATOLOGIC NEOPLASMS; HUMANS; MICROSATELLITE INSTABILITY; MUTATION; NEOPLASM PROTEINS;

EID: 84856405146     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.11.006     Document Type: Article

References (125)

1. P.A. Jones, S.B. Baylin The epigenomics of cancer Cell 128 2007 683 692 (Pubitemid 46273572)
2. J.A. Downs Chromatin structure and DNA double-strand break responses in cancer progression and therapy Oncogene 26 2007 7765 7772 (Pubitemid 350242456)
3. R.C. Allshire, G.H. Karpen Epigenetic regulation of centromeric chromatin: old dogs, new tricks? Nat Rev Genet 9 2008 923 937 (Pubitemid 50329068)
4. K.L. Rice, I. Hormaeche, J.D. Licht Epigenetic regulation of normal and malignant hematopoiesis Oncogene 26 2007 6697 6714 (Pubitemid 47585096)
5. J.P. Issa Epigenetic changes in the myelodysplastic syndrome Hematol Oncol Clin North Am 24 2010 317 330
6. R. Taby, J.P. Issa Cancer epigenetics CA Cancer J Clin 60 2010 376 392
7. R. Claus, M. Lubbert Epigenetic targets in hematopoietic malignancies Oncogene 22 2003 6489 6496 (Pubitemid 37372329)
8. R.S. Illingworth, A.P. Bird CpG islands'a rough guide' FEBS Lett 583 2009 1713 1720
9. J.A. Law, S.E. Jacobsen Establishing, maintaining and modifying DNA methylation patterns in plants and animals Nat Rev Genet 11 2010 204 220
10. M. Okano, D.W. Bell, D.A. Haber, E. Li DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development Cell 99 1999 247 257 (Pubitemid 29519904)
11. A. Hermann, R. Goyal, A. Jeltsch The Dnmt1 DNA-(cytosine-C5)- methyltransferase methylates DNA processively with high preference for hemimethylated target sites J Biol Chem 279 2004 48350 48359 (Pubitemid 39540991)
12. R. Singal, G.D. Ginder DNA methylation Blood 93 1999 4059 4070 (Pubitemid 29279247)
13. M.J. Hitchler, F.E. Domann Metabolic defects provide a spark for the epigenetic switch in cancer Free Radic Biol Med 47 2009 115 127
14. J. Boultwood, J.S. Wainscoat Gene silencing by DNA methylation in haematological malignancies Br J Haematol 138 2007 3 11 (Pubitemid 46889779)
15. M. Ehrlich DNA methylation in cancer: too much, but also too little Oncogene 21 2002 5400 5413 (Pubitemid 34983477)
16. V. Ambros, X. Chen The regulation of genes and genomes by small RNAs Development 134 2007 1635 1641 (Pubitemid 46796561)
17. R.Z. Chen, U. Pettersson, C. Beard, L. Jackson-Grusby, R. Jaenisch DNA hypomethylation leads to elevated mutation rates Nature 395 1998 89 93 (Pubitemid 28420236)
18. Y. Jiang, A. Dunbar, L.P. Gondek Aberrant DNA methylation is a dominant mechanism in MDS progression to AML Blood 113 2009 1315 1325
19. M.E. Figueroa, L. Skrabanek, Y. Li MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation Blood 114 2009 3448 3458
20. C.L. Di, V.A. Raker, M. Corsaro Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor Science 295 2002 1079 1082 (Pubitemid 34132239)
21. S.C. Wu, Y. Zhang Active DNA demethylation: many roads lead to Rome Nat Rev Mol Cell Biol 11 2010 607 620
22. A.M. Jankowska, L.P. Gondek, H. Szpurka, Z.P. Nearman, R.V. Tiu, J.P. Maciejewski Base excision repair dysfunction in a subgroup of patients with myelodysplastic syndrome Leukemia 22 2008 551 558 (Pubitemid 351386725)
23. P.W. Turk, A. Laayoun, S.S. Smith, S.A. Weitzman DNA adduct 8-hydroxyl-2'-deoxyguanosine (8-hydroxyguanine) affects function of human DNA methyltransferase Carcinogenesis 16 1995 1253 1255
24. G.D. Castro, C.J. Stamato, J.A. Castro 5-Methylcytosine attack by free radicals arising from bromotrichloromethane in a model system: structures of reaction products Free Radic Biol Med 17 1994 419 428
25. M. Tahiliani, K.P. Koh, Y. Shen Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by the MLL fusion partner TET1 Science 324 2009 930 935
26. S. Kriaucionis, N. Heintz The nuclear DNA base 5-hydroxymethylcytosine is present in purkinje neurons and the brain Science 324 2009 929 930
27. M. Ko, Y. Huang, A. Jankowska Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 Nature 468 2010 839 843
28. S. Ito, A.C. D'Alessio, O.V. Taranova, K. Hong, L.C. Sowers, Y. Zhang Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification Nature 466 2010 1129 1133
29. K.K. Lee, J.L. Workman Histone acetyltransferase complexes: one size doesn't fit all Nat Rev Mol Cell Biol 8 2007 284 295 (Pubitemid 46474661)
30. P.A. Marks, V.M. Richon, W.K. Kelly, J.H. Chiao, T. Miller Histone deacetylase inhibitors: development as cancer therapy Novartis Found Symp 259 2004 269 281
31. J.S. Ungerstedt, Y. Sowa, W.S. Xu Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors Proc Natl Acad Sci U S A 102 2005 673 678 (Pubitemid 40282724)
32. T. Jenuwein, C.D. Allis Translating the histone code Science 293 2001 1074 1080 (Pubitemid 32758077)
33. X. Zhang, Z. Yang, S.I. Khan Structural basis for the product specificity of histone lysine methyltransferases Mol Cell 12 2003 177 185 (Pubitemid 36957834)
34. C. Schoch, S. Schnittger, M. Klaus, W. Kern, W. Hiddemann, T. Haferlach AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases Blood 102 2003 2395 2402 (Pubitemid 37193575)
35. E. Pastural, N. Takahashi, W.F. Dong RIZ1 repression is associated with insulin-like growth factor-1 signaling activation in chronic myeloid leukemia cell lines Oncogene 26 2007 1586 1594 (Pubitemid 46398743)
36. Y. Shi, F. Lan, C. Matson Histone demethylation mediated by the nuclear amine oxidase homolog LSD1 Cell 119 2004 941 953 (Pubitemid 40037608)
37. R.J. Klose, E.M. Kallin, Y. Zhang JmjC-domain-containing proteins and histone demethylation Nat Rev Genet 7 2006 715 727 (Pubitemid 44260007)
38. G. van Haaften, G.L. Dalgliesh, H. Davies Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer Nat Genet 41 2009 521 523
39. S. Lim, E. Metzger, R. Schule, J. Kirfel, R. Buettner Epigenetic regulation of cancer growth by histone demethylases Int J Cancer 127 2010 1991 1998
40. T. Mahmoudi, C.P. Verrijzer Chromatin silencing and activation by polycomb and trithorax group proteins Oncogene 20 2001 3055 3066 (Pubitemid 32553560)
41. S. Swierczek, D. Yoon, K. Hickman, J.T. Prchal MicroRNA-101 is down-regulated in PV and ET granulocytes and its decrease is associated with over-expression of histone methyltransferase in EZH2 in MPN patients Blood (ASH Annual Meeting Abstracts) 116 2010 1989
42. M. Mohty, A.S. Yong, R.M. Szydlo, J.F. Apperley The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia Blood 110 2007 380 383 (Pubitemid 47026858)
43. + cells Blood 116 2010 4621 4630
44. G. Marcucci, M.D. Radmacher, K. Maharry MicroRNA expression in cytogenetically normal acute myeloid leukemia N Engl J Med 358 2008 1919 1928 (Pubitemid 351620112)
45. D.T. Starczynowski, R. Morin, A. McPherson Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations Blood 117 2011 595 607
46. D.T. Starczynowski, F. Kuchenbauer, B. Argiropoulos Identification of MiR-145 and MiR-146a as mediators of the 5q- syndrome phenotype Nat Med 16 2010 49 58
47. F. Fazi, S. Racanicchi, G. Zardo Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein Cancer Cell 12 2007 457 466 (Pubitemid 350046404)
48. R. Garzon, C.E. Heaphy, V. Havelange MicroRNA 29b functions in acute myeloid leukemia Blood 114 2009 5331 5341
49. A. Sallmyr, J. Fan, F.V. Rassool Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair Cancer Lett 270 2008 1 9
50. S. Negrini, V.G. Gorgoulis, T.D. Halazonetis Genomic instabilityan evolving hallmark of cancer Nat Rev Mol Cell Biol 11 2010 220 228
51. C.L. O'Keefe, M.A. McDevitt, J.P. Maciejewski Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies Blood 115 2010 2731 2739
52. R. Kralovics, F. Passamonti, A.S. Buser A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med 352 2005 1779 1790 (Pubitemid 40570926)
53. E.J. Baxter, L.M. Scott, P.J. Campbell Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 365 2005 1054 1061 (Pubitemid 40386783)
54. R.L. Levine, M. Wadleigh, J. Cools Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Cancer Cell 7 2005 387 397 (Pubitemid 40544655)
55. B. Vogelstein, K.W. Kinzler Cancer genes and the pathways they control Nat Med 10 2004 789 799 (Pubitemid 39070849)
56. T.J. Ley, L. Ding, M.J. Walter DNMT3A mutations in acute myeloid leukemia N Engl J Med 363 2010 2424 2433
57. Y. Yamashita, J. Yuan, I. Suetake Array-based genomic resequencing of human leukemia Oncogene 29 2010 3723 3731
58. M.J. Walter, D. Shen, J. Shao Recurrent DNMT3A mutations in patients with myelodysplastic syndrome Blood (ASH Annual Meeting Abstracts) 116 2010 608
59. A.M. Jankowska, H. Makishima, R.V. Tiu Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulationUTX, EZH2 and DNMT3A Blood 118 2011 3932 3941
60. W. Blum, R. Garzon, R.B. Klisovic Clinical response and MiR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine Proc Natl Acad Sci U S A 107 2010 7473 7478
61. V. Gelsi-Boyer, V. Trouplin, J. Adelaide Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia Br J Haematol 145 2009 788 800
62. R.D. Morin, N.A. Johnson, T.M. Severson Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin Nat Genet 42 2010 181 185
63. G. Nikoloski, S.M. Langemeijer, R.P. Kuiper Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes Nat Genet 42 2010 665 667
64. T. Ernst, A.J. Chase, J. Score Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders Nat Genet 42 2010 722 726
65. H. Makishima, A. Jankowska, R.V. Tiu Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies Leukemia 2010 10.1038/leu.2010.167 Epub ahead of print 19 August 2010
66. F. Xu, X. Li, L. Wu Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring Ann Hematol 90 2011 643 653
67. K. Agger, P.A. Cloos, J. Christensen UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development Nature 449 2007 731 734 (Pubitemid 47552088)
68. H. Szpurka, A.M. Jankowska, B. Przychodzen UTX mutations and epigenetic changes in MDS/MPN and related myeloid malignancies Blood (ASH Annual Meeting Abstracts) 116 2010 121
69. G.L. Sen, D.E. Webster, D.I. Barragan, H.Y. Chang, P.A. Khavari Control of differentiation in a self-renewing mammalian tissue by the histone demethylase JMJD3 Genes Dev 22 2008 1865 1870 (Pubitemid 352008635)
70. Z. Hu, I. Gomes, S.K. Horrigan A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31 Oncogene 20 2001 6946 6954 (Pubitemid 33052184)
71. + cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival Blood 112 2008 3412 3424
72. + hematoprogenitor cells Blood (ASH Annual Meeting Abstracts) 116 2010 609
73. L. Pasqualucci, D. Dominguez-Sola, A. Chiarenza Genome-wide analysis reveals frequent inactivating mutations of acetyltransferase genes in B-cell lymphoma Blood (ASH Annual Meeting Abstracts) 116 2010 474
74. C. Mullighan, J. Zhang, L.H. Kasper CREBBP mutations in relapsed acute lymphoblastic leukemia Blood (ASH Annual Meeting Abstracts) 116 2010 413
75. A. Kohlmann, V. Grossmann, H.U. Klein Targeted next-generation sequencing (NGS) enables a broad screening of 95 molecular mutations in a one-step approach and detects recurrent mutations in AML with a normal karyotype in MYH11 and NOTCH1 Blood (ASH Annual Meeting Abstracts) 116 2010 175
76. Y.S. Cho, E.J. Kim, U.H. Park, H.S. Sin, S.J. Um Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor J Biol Chem 281 2006 17588 17598
77. V. Gelsi-Boyer, V. Trouplin, J. Roquain ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia Br J Haematol 151 2010 365 375
78. N. Carbuccia, A. Murati, V. Trouplin Mutations of ASXL1 gene in myeloproliferative neoplasms Leukemia 23 2009 2183 2186
79. J. Boultwood, J. Perry, A. Pellagatti Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia Leukemia 24 2010 1139 1145
80. N. Carbuccia, V. Trouplin, V. Gelsi-Boyer Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias Leukemia 24 2010 469 473
81. J. Boultwood, J. Perry, R. Zaman High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression Leukemia 24 2010 1139 1145
82. C.L. Fisher, N. Pineault, C. Brookes Loss-of-function additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia Blood 115 2010 38 46
83. K.M. Lower, G. Turner, B.A. Kerr Mutations in PHF6 are associated with Borjeson-Forssman-Lehmann syndrome Nat Genet 32 2002 661 665 (Pubitemid 35435181)
84. P. Van Vlierberghe, T. Palomero, H. Khiabanian PHF6 mutations in T-cell acute lymphoblastic leukemia Nat Genet 42 2010 338 342
85. P. Van Vlierberghe, J. Patel, O. Abdel-Wahab PHF6 mutations in adult acute myeloid leukemia Leukemia 25 2011 130 134
86. F. Delhommeau, S. Dupont, V. Della Mutation in TET2 in myeloid cancers N Engl J Med 360 2009 2289 2301
87. S.M. Langemeijer, R.P. Kuiper, M. Berends Acquired mutations in TET2 are common in myelodysplastic syndromes Nat Genet 41 2009 838 842
88. A.M. Jankowska, H. Szpurka, R.V. Tiu Loss of heterozygosity 4q42 and TET2 mutations associated with myelodysplatic/myeloproliferative neoplasms Blood 113 2009 6403 6410
89. A. Tefferi, A. Pardanani, K.H. Lim TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis Leukemia 23 2009 905 911
90. F. Mohr, K. Dohner, C. Buske, V.P. Rawat TET genes: new players in DNA demethylation and important determinants for stemness Exp Hematol 39 2011 272 281
91. O. Abdel-Wahab, A. Mullally, C. Hedvat Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies Blood 114 2009 144 147
92. M.E. Figueroa, O. Abdel-Wahab, C. Lu Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation Cancer Cell 18 2010 553 567
93. Y. Sugimoto, H. Muramatsu, H. Makishima Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations Br J Haematol 150 2010 83 87
94. B. Perez, O. Kosmider, B. Cassinat Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia Br J Haematol 151 2010 460 468
95. P.A. Ho, T.A. Alonzo, K.J. Kopecky Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study Leukemia 24 2010 909 913
96. D.W. Parsons, S. Jones, X. Zhang An integrated genomic analysis of human glioblastoma multiforme Science 321 2008 1807 1812
97. E.R. Mardis, L. Ding, D.J. Dooling Recurring mutations found by sequencing an acute myeloid leukemia genome N Engl J Med 361 2009 1058 1066
98. P.S. Ward, J. Patel, D.R. Wise The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate Cancer Cell 17 2010 225 234
99. S. Gross, R.A. Cairns, M.D. Minden Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations J Exp Med 207 2010 339 344
100. W.C. Chou, H.A. Hou, C.Y. Chen Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation Blood 115 2010 2749 2754
101. G. Marcucci, K. Maharry, Y.Z. Wu IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study J Clin Oncol 28 2010 2348 2355
102. P. Paschka, R.F. Schlenk, V.I. Gaidzik IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication J Clin Oncol 28 2010 3636 3643
103. A. Tefferi, T.L. Lasho, O. Abdel-Wahab IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis Leukemia 24 2010 1302 1309
104. K. Wagner, F. Damm, G. Gohring Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP Rs11554137 is an adverse prognostic factor J Clin Oncol 28 2010 2356 2364
105. L. Dang, D.W. White, S. Gross Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 462 2009 739 744
106. M.A. Dawson, A.J. Bannister, B. Gottgens JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin Nature 461 2009 819 822
107. F. Stegelmann, R.F. Schlenk, M. Griesshammer Mutations of EZH2 in myeloproliferative neoplasms with myelofibrosis: correlation with molecular and clinical data Blood (ASH Annual Meeting Abstracts) 116 2010 4111
108. V. Grossmann, A. Kohlmann, C. Eder Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance Leukemia 25 2011 877 879
109. O. Abdel-Wahab, A. Pardanani, J. Patel Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms Blood (ASH Annual Meeting Abstracts) 116 2010 3070
110. O. Abdel-Wahab, T. Manshouri, J. Patel Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias Cancer Res 70 2010 447 452
111. H. Szpurka, A.M. Jankowska, H. Makishima Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations Leuk Res 34 2010 969 973
112. J. Rocquain, N. Carbuccia, V. Trouplin Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias BMC Cancer 10 2010 401
113. W.C. Chou, H.H. Huang, H.A. Hou Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations Blood 116 2010 4086 4094
114. A. Tefferi, R.L. Levine, K.H. Lim Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates Leukemia 23 2009 900 904
115. A. Tefferi, K.H. Lim, O. Abdel-Wahab Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML Leukemia 23 2009 1343 1345
116. O. Kosmider, V. Gelsi-Boyer, M. Cheok TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs) Blood 114 2009 3285 3291
117. O. Kosmider, V. Gelsi-Boyer, M. Ciudad TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia Haematologica 94 2009 1676 1681
118. C. Saint-Martin, G. Leroy, F. Delhommeau Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms Blood 114 2009 1628 1632
119. J. Flach, F. Dicker, S. Schnittger, A. Kohlmann, T. Haferlach, C. Haferlach Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis Haematologica 95 2010 518 519
120. H. Muramatsu, H. Makishima, A.M. Jankowska Mutations of an E3 Ubiquitin Ligase C-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia Blood 115 2010 1969 1975
121. O. Nibourel, O. Kosmider, M. Cheok Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission Blood 116 2010 1132 1135
122. A. Kohlmann, V. Grossmann, H.-U. Klein Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia (CMML) by detecting frequent alterations in TET2, CBL, RAS and RUNX1 J Clin Oncol 28 2010 3858 3865
123. A.E. Smith, A. Mahamedali, A. Kulasekararaj Next-generation sequencing of the TET2 gene in 355 MDS patients reveals low abundance mutant clones with early origins, but indicates no definite prognostic value Blood 116 2010 3923 3932
124. O. Kosmider, V. Gelsi-Boyer, L. Slama Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms Leukemia 24 2010 1094 1096
125. S. Abbas, S. Lugthart, F.G. Kavelaars acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value Blood 116 2010 2122 2126